The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

Bank of America Securities analyst Travis Steed maintained a Buy rating on Boston Scientific (BSX – Research Report) today. The ...

Medical-products company Boston Scientific reported third-quarter results before market open Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Boston Scientific BSX is gaining traction in the international markets. New regulatory approvals and accretive acquisitions ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

The medical device maker's adjusted earnings per share and revenue were more than expected, as sales of its cardiovascular products surged. Boston Scientific gave a mixed updated full-year forecast.

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...